| Literature DB >> 35336712 |
Mohamed S Abd El Hafeez1, Omayma El Gindi1, Mona H Hetta2, Hanan F Aly3, Safwat A Ahmed4.
Abstract
Colvillea racemosa is a cultivated ornamental plant that is a monotypic genus of Fabaceae. It is native to Madagascar, with limited studies. For the first time, the leaf quality control parameters, the anti-hyperglycemic and anti-inflammatory in vitro activity of Colvillea racemosa ethanol extract (CRE) and its fractions of petroleum ether (CRP), methylene chloride (CRMC), ethyl acetate (CREA), n-butanol (CRB), and methanol (CRME) were evaluated. It exhibited significant inhibition against α-amylase, α-glucosidase and membrane stabilization. CRB was the most active fraction, and in vivo studies revealed that oral treatment with CRB of STZ-induced diabetic rats efficiently lowered blood glucose by 67.78%, reduced serum nitric oxide and lipid peroxide levels by 41.23% and 38.45%, respectively, and increased the GSH level by 90.48%. In addition, compared with the diabetic group, there was a 52.2% decrease in serum VCAM, a 55.5% increase in paraoxonase, an improved lipid profile, and improved liver and kidney functions for a treated diabetic group with CRB. Metabolite profiling of CRB was determined by UPLC-ESI-QTOF-MS and tandem MS/MS. Twenty-three chromatographic peaks were identified, which were classified into phenolic compounds and amino acids. The characterized flavonoids were apigenin and luteolin derivatives.Entities:
Keywords: Colvillea racemosa; UPLC-ESI-QTOF-MS; anti-hyperglycemic activity; anti-inflammatory; tandem MS/MS; α-amylase; α-glucosidase
Year: 2022 PMID: 35336712 PMCID: PMC8948708 DOI: 10.3390/plants11060830
Source DB: PubMed Journal: Plants (Basel) ISSN: 2223-7747
Proximate composition (on a dry matter basis) of Colvillea racemosa leaves.
| Proximate Composition | (g/100 g) | Proximate Composition | (g/100 g) |
|---|---|---|---|
| Moisture % | 8.2 ± 0.4 | Total carbohydrate % | 49.03 ± 2.1 |
| Ash % | 13 ± 1.3 | Total lipid % | 11.74 ± 0.32 |
| Fiber % | 14.44 ± 0.83 | Total protein % | 26.23 ± 0.55 |
| Energy value (Kcal/100 g) | 394.4425 (Kcal/100 g) | ||
Values are (mean of triplicate ± standard deviation).
Mineral contents (on a dry matter basis) of Colvillea racemosa leaves.
| Element | mg/100 g | RDI * (mg) | MDI * (mg) |
|---|---|---|---|
| Na | 186.03 | 1500–2300 | 2300 |
| Mg | 344.01 | 310–420 | 350 |
| K | 2001.90 | 4700–5000 | N.D |
| Ca | 2426.67 | 1000–1300 | 2500 |
| Mn | 8.86 | 1.8–2.3 | 11 |
| Cu | 0.705 | 0.9 | 10 |
| Zn | 2.965 | 8–11 | N.D |
| Se | N.D | 0.055 | 0.4 |
| Cd | N.D | 0.02 | 0.02 |
| Pb | N.D | 0.0125 | 0.0125 |
* RDI: recommended daily intake for adults [17,18]. * MDI: maximum daily intake for adult [17,18]. N.D: not detected.
Figure 1(a) α-Amylase inhibition percentage, (b) α-glucosidase inhibition percentage, and (c) membrane stabilization inhibition percentage of Colvillea racemosa ethanol extract (CRE) and its fractions (petroleum ether (CRP), methylene chloride (CRMC), ethyl acetate (CREA), n-butanol (CRB), and methanol (CRME)). STD (acarbose (a,b)and indomethacin (c)).
Figure 2Effect of the n-butanol fraction of Colvillea racemosa total extract (CRB) oral administration on the pancreatic activity in diabetic STZ-treated rats: glucose (A) and α-amylase activity (B). Results are shown as means ± S.D. (measured in triplicate; n = 3). Means that have different letters are significantly different (p < 0.05).
Effect of the n-butanol fraction of Colvillea racemosa total extract (CRB) orally administered on lipid profile (mg/dL) in Streptozotocin (STZ)-induced diabetic rats.
| Groups | Total Lipid | Triglycerides | Total Cholesterol | HDL-Cholesterol | |
|---|---|---|---|---|---|
| 1 | Normal rats | 574.11 ± 29.35 a | 111.20 ± 2.19 c | 140.90 ± 20.05 a | 50.10 ± 1.28 a |
| 2 | Normal rats treated with CRB | 600.11 ± 20.33 a | 110.22 ± 9.50 bc | 148.20 ± 9.00 a | 51.11 ± 1.08 a |
| 3 | STZ-treated diabetic rats | 910.20 ± 20.00 b | 170.92 ± 6.05 b | 220.40 ± 8.10 b | 30.10 ± 2.00 b |
| 4 | STZ—diabetic rats treated with CRB | 611.11 ± 39.28 a | 135.20 ± 7.13 a | 154.90 ± 10.40 a | 52.00 ± 2.70 a |
| 5 | STZ—diabetic rats treated with GLB | 670.70 ± 29.00 a | 128.00 ± 8.20 ac | 143.00 ± 6.10 a | 53.10 ± 2.30 a |
Results are displayed as means ± S.D. (measured in triplicate; n = 3). Means with different letters are significantly different (p < 0.05).
Effect of n-butanol fraction of Colvillea racemosa total extract (CRB) orally administered on liver function in Streptozotocin (STZ)-induced diabetic rats.
| Groups | ALT | AST | ALP | Bilirubin | Total Protein | |
|---|---|---|---|---|---|---|
| 1 | Normal rats | 80.71 ± 2.40 a | 144.20 ± 10.55 a | 94.71 ± 1.91 a | 0.60 ± 0.09 a | 5.59 ± 0.21 a |
| 2 | Normal rats treated with CRB | 83.00 ± 2.60 a | 140.50 ± 4.10 a | 97.11 ± 1.68 a | 0.60 ± 0.07 a | 5.24 ± 0.38 a |
| 3 | STZ-treated diabetic rats | 170 ± 11.00 b | 230.54 ± 10.20 b | 163.44 ± 15.44 b | 1.20 ± 0.10 b | 3.67 ± 0.36 b |
| 4 | STZ—diabetic rats treated with CRB | 96.20 ± 8.30 ac | 158.80 ± 5.90 a | 99.48 ± 6.60 a | 0.70 ± 0.02 a | 5.25 ± 0.33 a |
| 5 | STZ—diabetic rats treated with GLB | 89.22 ± 6.70 a | 140.00 ± 8.80 a | 96.03 ± 11.50 a | 0.65 ± 0.02 a | 5.16 ± 0.69 a |
Results are displayed as means ± S.D. (measured in triplicate; n = 3). Means with different letters are significantly different (p < 0.05).
Effect of n-butanol fraction of Colvillea racemosa total extract (CRB) orally administered on kidney function (mg/dL) in Streptozotocin (STZ)-induced diabetic rats.
| Groups | Creatinine Level | Urea Activity | |
|---|---|---|---|
| 1 | Normal rats | 0.26 ± 0.02 b | 32.70 ± 2.52 b |
| 2 | Normal rats treated with CRB | 0.25 ± 0.09 b | 30.95 ± 1.70 b |
| 3 | STZ-treated diabetic rats | 0.49 ± 0.07 a | 60.59 ± 2.06 a |
| 4 | STZ—diabetic rats treated with CRB | 0.29 ± 0.05 b | 36.22 ± 3.32 b |
| 5 | STZ—diabetic rats treated with GLB | 0.25 ± 0.06 b | 33.55 ± 2.72 b |
Results are displayed as means ± S.D. (measured in triplicate; n = 3). Means with different letters are significantly different (p < 0.05).
Figure 3Effect of the n-butanol fraction of Colvillea racemosa total extract (CRB) oral administration on oxidative stress markers in Streptozotocin (STZ)-induced diabetic rats; GSH level (A), nitric oxide level (B), lipid peroxidase level (C), GPX activity (D), GST activity (E), and catalase activity (F). Results are displayed as means ± S.D. (measured in triplicate; n = 3). Means with different letters are significantly different (p < 0.05).
Figure 4Effect of n-butanol fraction of Colvillea racemosa total extract (CRB) oral administration on inflammatory markers in Streptozotocin (STZ)-induced diabetic rats: VCAM level (A), ICAM-1 level (B), IL1-β level (C), paraoxonase activity (D), TNF-α level (E), and TGF-β level (F). Results are displayed as means ± S.D. (measured in triplicate; n = 3). Means with different letters are significantly different (p < 0.05).
Figure 5Histopathological examination for (1) liver. (a) Liver from the standard group, (b) liver from positive diabetic rats, (c) liver from the group treated with CRB (Lesion Score: 0), (d) liver from the group treated with CRB (Lesion Score: +) and (e) liver from the group treated with standard drug (Lesion Score: ++).
Figure 6Histopathological examination for (2) pancreas. (a) Pancreas from the standard group (Lesion Score: 0), (b) pancreas from the positive diabetic group (Lesion Score: ++++), (c) pancreas from the group treated with CRB (Lesion Score: 0), (d) pancreas from the group treated with CRB (Lesion Score: +) and (e) pancreas from the group treated with standard drug (Lesion Score: ++).
Figure 7Histopathological examination for (3) kidney. (a) Photomicrograph of hematoxylin-and-eosin-stained section of normal renal rats, (b) photomicrograph of the group of diabetic renal rats treated with CRB (Lesion Score: +), (c) photomicrograph of renal diabetes-positive rats (Lesion score +++) and (d) photomicrograph of renal diabetic rats treated with standard drug (Lesion score+).
Figure 8Base peak chromatogram of the n-butanol fraction of Colvillea racemosa total extract (CRB) in positive mode at wavelength 250 nm.
Metabolite profiling of CRB via UPLC-ESI-QTOF-MS in positive mode.
| No. | RT (min) | [M + H]+ | M | Molecular Formula | Score | Error (mDa) | MS/MS | Proposed Compound | Area | Reference |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 3.499 | 116.0706 | 115.0633 | C5H9NO2 | 99.21 | −0.01 | 99.0504, 98.0604 | Proline | 2.14 × 106 | [ |
| 2 | 3.566 | 146.0814 | 145.0741 | C6H11NO3 | 97.69 | −0.22 | 128.0704, 100.0758 | Hydroxypipecolic acid I | 1.52 × 108 | [ |
| 3 | 3.634 | 118.0865 | 117.0789 | C5H11NO2 | 87.69 | −0.27 | 59.0735 | Hydroxymethyl hydroxypyrrolidine I | 4.71 × 106 | [ |
| 4 | 3.768 | 118.0864 | 117.0789 | C5H11NO2 | 99.71 | −0.16 | 72.0813, 59.0736 | Hydroxymethyl hydroxypyrrolidine II | 1.08 × 107 | [ |
| 5 | 4.374 | 118.0862 | 117.0789 | C5H11NO2 | 97.04 | 0.07 | 59.0731 | Hydroxymethyl hydroxypyrrolidine III | 1.81 × 106 | [ |
| 6 | 4.576 | 146.0816 | 145.0741 | C6H11NO3 | 97.23 | −0.46 | 128.0702, 100.0756 | Hydroxypipecolic acid II | 4.80 × 107 | [ |
| 7 | 4.644 | 294.155 | 293.1477 | C12H23NO7 | 99.29 | 0.12 | 132.1016, 86.0966 | Leucine/Isoleucine hexoside | 5.13 × 106 | [ |
| 8 | 4.711 | 132.1019 | 131.0945 | C6H13NO2 | 99.94 | −0.02 | 86.0966 | Leucine/Isoleucine I | 1.34 × 107 | [ |
| 9 | 4.913 | 132.1021 | 131.0945 | C6H13NO2 | 99.5 | −0.2 | 86.0967 | Leucine/Isoleucine II | 1.03 × 107 | [ |
| 10 | 6.26 | 166.0867 | 165.0793 | C9H11NO2 | 98.66 | −0.36 | 149.0597, 121.0836, 120.0807, 105.0710 | Phenylalanine | 1.43 × 107 | [ |
| 11 | 10.905 | 611.1618 | 610.1543 | C27H30O16 | 97.7 | −0.92 | 593.1504, 575.1391, 515.1195, 473.1074, 353.0630 | Luteolin di | 2.19 × 106 | [ |
| 12 | 11.275 | 595.1679 | 594.1585 | C27H30O15 | 93.44 | −1.93 | 577.1558, 559.1454, 475.1237, 457.1130, 335.0805, 307.0607, 137.1056, 135.0897, 133.0836 | Luteolin | 1.29 × 107 | [ |
| 13 | 11.951 | 579.1725 | 578.1653 | C27H30O14 | 90.32 | −1.72 | N.D. | Apigenin | 8.18 × 105 | [ |
| 14 | 12.184 | 595.1682 | 594.1585 | C27H30 O15 | 91.47 | −2.19 | 449.1085, 287.0549, 153.0187, 137.0227 | Luteolin | 9.25 × 106 | [ |
| 15 | 12.454 | 433.1142 | 432.1062 | C21H20O10 | 96.03 | −1.23 | 415.1026, 397.0927, 367.0809, 337.0705, 119.0506 | Apigenin | 9.40 × 106 | [ |
| 16 | 12.588 | 449.1087 | 448.1015 | C21H20O11 | 97.24 | −0.98 | 287.054,153.0189,135.0438,121.0623 | Luteolin | 3.31 × 106 | [ |
| 17 | 12.652 | 579.1725 | 578.1653 | C27H30O10 | 95.91 | −1.38 | 431.1131, 271.0599 153.0174 | Apigenin | 4.90 × 106 | [ |
| 18 | 13.262 | 433.1142 | 432.1062 | C21H20O10 | 98.94 | −1.25 | 271.0600, 153.0181, 119.0484 | Apigenin | 9.21 × 106 | [ |
| 19 | 13.463 | 285.0947 | 284.0874 | C13H16O7 | 84.36 | 1.91 | 123.0183, 79.0543 | Benzoyl hexoside | 2.70 × 106 | [ |
| 20 | 13.935 | 373.1472 | 372.1403 | C17H24O9 | 90.71 | 1.69 | 329.0868, 299.1014, 211.0896 | Syringin | 3.36 × 106 | [ |
| 21 | 14.339 | 385.1463 | 384.1399 | C18H24O9 | 86.72 | 2.15 | 223.1290, 221.0660, 173.0804 | Ethylferulate hexoside | 3.53 × 106 | [ |
| 22 | 15.753 | 287.0552 | 286.048 | C15H10O6 | 99.71 | −0.24 | 153.0189, 135.0438, 121.0623 | Luteolin | 5.70 × 106 | [ |
| 23 | 16.695 | 271.0602 | 270.0528 | C15H10O5 | 99.24 | −0.18 | N.D. | Apigenin | 3.37 × 106 | [ |
N.D., non-detected.